Content Hub

In this in depth interview, Rachelle Prantil Baun, Principal Scientist at Novo Nordisk and leading expert in complex in vitro models (CIVMs), microphysiological systems (MPS) and organs on chips, discusses her 20 year career developing advanced 3D tissue models, translational disease models, and early stage drug discovery platforms.

The conversation explores the future of human relevant preclinical models, the impact of the FDA Modernization Act 2.0/3.0, evolving regulatory expectations, model robustness, and how the biopharma industry can accelerate adoption of 3D in vitro systems for toxicity, efficacy, and translational research.

Rachelle also explains why the 11th 3D Tissue Models Summit is essential for industry, academia, and government stakeholders - particularly those focused on reducing animal testing, improving model reproducibility, advancing regulatory science, and building collaborative, multidisciplinary approaches to drug discovery and safety assessment.

This interview offers valuable perspectives for scientists, model developers, regulatory specialists, and R&D leaders working at the intersection of 3D tissue engineering, complex in vitro models, and next generation preclinical testing technologies.